Skip Navigation

AIDSInfo-at-a-glance

Issue No. 12 | May 23, 2014
A Service of the U.S. Department of Health and Human ServicesView HTML version
News and Features 

AIDSinfo and infoSIDA Websites Now Optimized for Display on Mobile Devices

AIDSinfo recently updated the AIDSinfo and infoSIDA websites, and they are now automatically optimized for display across all devices—desktop computers, tablets, and smartphones. Visitors to the AIDSinfo and infoSIDA websites will now be able to access all of the website content on any device they are using.

We decided to create a responsive design website—a site that automatically adjusts to any device—because of a shift in ways people are accessing the Internet. Between 2010 and 2014, mobile traffic to the AIDSinfo website increased 10-fold, and almost 90% of health care providers surveyed on the AIDSinfo website have Internet access at the point of care (i.e., while caring for patients), and of those, more than 2/3 use a mobile device when seeing patients. With this redesign, health care providers, researchers, people with HIV/AIDS, their family and friends, and anyone who visits the website will now be able to access the HIV/AIDS medical practice guidelines, drug database, fact sheets, clinical trials search, HIV/AIDS glossary, and all of the other website features in an easy-to-navigate format no matter what device they are using.

If you have saved the mobile site URLs (http://m.aidsinfo.nih.gov/ and http://m.infosida.nih.gov/) as a Bookmark or Favorite on your tablet or smartphone, there is no need to worry! These URLs will be automatically forwarded to the responsive design website.

We would love to hear from you! Please send your questions or feedback about the responsive design website to ContactUs@aidsinfo.nih.gov

CDC Announces Release of New Clinical Practice Guidelines for PrEP Use

New guidelines developed by CDC in partnership with other federal health agencies, public health experts, and community leaders update recommendations on the use of pre-exposure prophylaxis (PrEP) for the prevention of HIV infection in adults in the United States. The guidelines recommend that health care providers consider PrEP for people who are at substantial risk for HIV infection.

The new guidelines include recommended indications for PrEP use; information on Truvada (emtricitabine/tenofovir disoproxil fumarate), the FDA-approved drug for use as PrEP in combination with safer sex practices; and advice for providers on how to support medication adherence.

More information is available:

• CDC: Press release
• CDC: PrEP webpage
• AIDSinfo: Truvada patient fact sheet

Recent HIV/AIDS News from CDC, NIH, and FDA

News from CDC

May 21, 2014: New CDC Campaign Inspires Life-Saving Conversations About HIV

“The Centers for Disease Control and Prevention today launched Start Talking. Stop HIV., a new national communication campaign encouraging gay and bisexual men to talk openly with their sexual partners about HIV risk and prevention strategies.”

News from NIH

May 19, 2014: 2014 Avant-Garde Awards Focus on Strengthening the Immune System

“With proposals ranging from enhancing the immune system’s ability to fight HIV infection to improving long-term immune health in HIV-infected drug users, three scientists have been chosen to receive the 2014 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.” 

News from FDA

May 12, 2014: Tivicay (Dolutegravir) Labeling Update

“On May 12, 2014, FDA approved updates to the TIVICAY (dolutegravir) product labeling with information regarding the effect of dolutegravir on renal transporters and drug-drug interaction data between dolutegravir and calcium carbonate or ferrous fumarate.”

View the AIDSinfo patient fact sheet on dolutegravir.

Home | Guidelines | Clinical Trials | Drugs | Health Topics | Education Materials | Mobile Resources & Tools
Unsubscribe | Contact Us
Left footer corner image Left footer corner image